EUCTR2004-000555-42-IT进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO
sanofi-aventis Recherche & De`veloppement0 个研究点目标入组 870 人开始时间: 2004年11月23日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects meeting all of the following criteria will be considered for enrollment into the study: - MS subjects, aged 18 to 55, who are ambulatory (EDSS less or equal than 5.5) - Exhibiting a relapsing clinical course, with or without progression (Relapsing Remitting, Secondary Progressive or Progressive Relapsing) - Meeting McDonald¿s criteria for MS diagnosis - Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial - No relapse onset in the preceding 60 days prior to randomization - During the 4 weeks prior to randomization, subjects must have been clinically stable, without adrenocorticotrophic hormone (ACTH) or systemic steroid treatment - Signed main informed consent form and the informed consent for HIV testing
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia - Subjects with a congenital or acquired severe immunodeficiency, a history of cancer, lymphoproliferative disease, or any subject who has received lymphoid irradiation - Human immunodeficiency virus (HIV) positive status; known history of active tuberculosis not adequately treated; persistent significant or severe infection - Pregnancy, breastfeeding, subjects wishing to parent children during the course of the trial - Therapies that are disallowed - Subjects must not have used ACTH or systemic corticosteroids for 4 weeks prior to randomization - Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents - Prior use of natalizumab (Tysabri) - Prior use of interferons or cytokine therapy in the preceding 4 months; prior use of glatiramer acetate therapy in the preceding 6 months; prior use of intravenous immunoglobulins in the preceding 6 months; prior use of any investigational drug in the preceding 6 months; previous treatment with teriflunomide or leflunomide (ARAVA®) - Contraindication for MRI - Liver function impairment or persisting elevations of SGPT/ALT, serum glutamic oxaloacetic transaminase (SGOT/AST), or direct bilirubin greater than 1.5-fold the upper limit of normal (ULN); - Persisting elevations of serum amylase or lipase greater than 2-fold the upper limit of normal - Known history of active hepatitis - Hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin <3.0 g/dL - Known history of chronic pancreatic disease or pancreatitis - Moderate to severe impairment of renal function, as shown by serum creatinine >133 µmol/L (or >1.5 mg/dL) - Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol - Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the subject at risk by participating in the study - History of drug or alcohol abuse - Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study - Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients with Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and are Treated with Insulin (ODYSSEY DM - Insulin)MedDRA version: 20.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2015-000799-92-DEsanofi-aventis Groupe500
已完成
1 期
A clinical study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of S0597 by intranasal route in healthy male subjectsCTRI/2010/091/001413Sun Pharma Advanced Research Company Ltd40
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapyOral mucositisMedDRA version: 9.1Level: LLTClassification code 10028130Term: Mucositis oralEUCTR2008-005565-54-SKBiotec Pharmacon ASA120
进行中（未招募）
1 期
Proof of concept study of rilzabrutinib in adult participants with moderate-to-severe asthmaAsthmaEUCTR2021-002490-26-ESSanofi aventis recherche et developpement213
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseEUCTR2015-000990-11-GBBayer AG9,600